<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d2fe0d3b-8eb6-4e54-8418-642f330abbf7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DILAUDID<sup>®</sup> INJECTION safely and effectively.<br/>See full prescribing information for DILAUDID<sup>®</sup> INJECTION.<br/>DILAUDID<sup>®</sup> INJECTION (hydromorphone hydrochloride) for intravenous, intramuscular, or subcutaneous use, CII <br/>Initial U.S. Approval: January 1984
</title>
   <effectiveTime value="20240101"/>
   <setId root="9eebd88a-5632-460f-b7b6-26c8a180540d"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC
</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="964475045" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76045-010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76045-009" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76045-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76045-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76045-009" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76045-010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="37852017-235a-423e-a54e-2618aecc782f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20190122"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76045-009" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dilaudid<suffix/>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Hydromorphone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="L960UP2KRW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROMORPHONE HYDROCHLORIDE
</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q812464R06" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROMORPHONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76045-009-96" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76045-009-06" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20181204"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76045-009-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76045-009-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20181204"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019034" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181204"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76045-010" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dilaudid<suffix/>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Hydromorphone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="L960UP2KRW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROMORPHONE HYDROCHLORIDE
</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q812464R06" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROMORPHONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76045-010-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76045-010-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20161216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019034" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20161216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76045-121" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dilaudid<suffix/>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Hydromorphone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="L960UP2KRW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROMORPHONE HYDROCHLORIDE
</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q812464R06" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROMORPHONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76045-121-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76045-121-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019034" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20161216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="630fd1b3-b2cc-4236-8b93-bdae15d692dd"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="80.950%" align="left"/>
                           <col width="19.050%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)
</td>
                                 <td align="right" valign="top">10/2019
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="7121e598-b934-4ba7-97d3-d36da94a8aaf"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
</title>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">DILAUDID INJECTION exposes users to risks of addictions, abuse, and misuse, which can lead to overdose and death.  Assess patient's risk before prescribing and monitor regularly for these behaviors and conditions. (<linkHtml href="#s23">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur.  Monitor closely, especially upon initiation or following a dose increase. (<linkHtml href="#s24">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Prolonged use of DILAUDID INJECTION during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.  If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (<linkHtml href="#s25">5.3</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. (<linkHtml href="#s26">5.4</linkHtml>, <linkHtml href="#s41">7</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="cc4590fd-9a38-441c-991e-4d3311e010af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Addiction, Abuse, and Misuse</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">DILAUDID INJECTION exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing DILAUDID INJECTION and monitor all patients regularly for the development of these behaviors and conditions </content>
                           <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s23">5.1</linkHtml>)]</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="37214250-d629-440a-8ede-37d0fe4f47da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Life-Threatening Respiratory Depression</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur with use of DILAUDID INJECTION.  Monitor for respiratory depression, especially during initiation of DILAUDID INJECTION or following a dose increase
</content>
                           <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="55adc3c8-acdd-47e9-812a-6d374b5195c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Neonatal Opioid Withdrawal Syndrome</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Prolonged use of DILAUDID INJECTION during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available
</content>
                           <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s25">5.3</linkHtml>)]</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="81a4933d-6002-451d-b3b1-9b16b46ebfae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death
</content>
                           <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s26">5.4</linkHtml>), Drug Interactions (<linkHtml href="#s41">7</linkHtml>)].</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Reserve concomitant prescribing of DILAUDID Injection and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Limit dosages and durations to the minimum required.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Follow patients for signs and symptoms of respiratory depression and sedation.</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="3726b809-026f-47e2-85bc-8c90d897b54e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.
</paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DILAUDID INJECTION is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. (<linkHtml href="#s7">1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Have not been tolerated, or are not expected to be tolerated
</item>
                           <item>Have not provided adequate analgesia, or are not expected to provide adequate analgesia
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8">
                     <id root="ab06dd69-4ba7-489c-9087-fc4ea4ab1157"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.1</linkHtml>)]</content>, reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Have not been tolerated, or are not expected to be tolerated
</item>
                           <item>Have not provided adequate analgesia, or are not expected to provide adequate analgesia
</item>
                        </list>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="b2c65150-eaa4-47ff-9f1d-6d6dabb7362a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse. (<linkHtml href="#s10">2.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Initial Dosage:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <caption>-
</caption>
                                    <content styleCode="italics">Intramuscular or Subcutaneous Use</content>: The usual starting dose is 1 mg to 2 mg every 2 to 3 hours as necessary. (<linkHtml href="#s11">2.2</linkHtml>)
</item>
                                 <item>
                                    <caption>-
</caption>
                                    <content styleCode="italics">Intravenous Use</content> : The usual starting dose is 0.2 mg to 1 mg every 2 to 3 hours. The injection should be given slowly<content styleCode="bold">,</content> over at least 2 to 3 minutes. (<linkHtml href="#s11">2.2</linkHtml>)
</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Hepatic Impairment</content>: Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of hepatic impairment. (<linkHtml href="#s16">2.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Renal Impairment</content>: Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of renal impairment. (<linkHtml href="#s17">2.4</linkHtml>)
</item>
                           <item>Do not stop DILAUDID INJECTION abruptly in a physically-dependent patient (<linkHtml href="#s19">2.6</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s10">
                     <id root="5329e1c0-d5a0-4f9e-ac45-280a2ae0d4e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosage and Administration Instructions
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5</linkHtml>)].</content>
                           </item>
                           <item>Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.1</linkHtml>)].</content>
                           </item>
                           <item>Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with DILAUDID INJECTION and adjust the dosage accordingly <content styleCode="italics">[see Warnings and Precautions  (<linkHtml href="#s24">5.2</linkHtml>)].</content>
                           </item>
                           <item>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. A slight yellowish discoloration may develop in DILAUDID INJECTION. No loss of potency has been demonstrated. DILAUDID INJECTION is physically compatible and chemically stable for at least 24 hours at 25°C, protected from light in most common large-volume parenteral solutions.
</item>
                           <item>Discard any unused portion in an appropriate manner.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="e3b3dd4f-a687-4520-ad70-f0fc9d98580d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Initial Dosage
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s12">
                           <id root="584ce812-3972-49a3-90ae-ea9bad18ac4f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Use of DILAUDID INJECTION as the First Opioid Analgesic:</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                           <component>
                              <section ID="s13">
                                 <id root="6deade2d-8696-422f-a8bc-8e0139eaac6f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Subcutaneous or Intramuscular Administration:</content>
                                    </paragraph>
                                    <paragraph>The usual starting dose of DILAUDID INJECTION is 1 mg to 2 mg every 2 to 3 hours as necessary. Depending on the clinical situation, the initial starting dose may be lowered in patients who are opioid naïve.
</paragraph>
                                 </text>
                                 <effectiveTime value="20200131"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s14">
                                 <id root="e749d2b7-ec39-446c-886a-5ea40e876591"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Intravenous Administration:</content>
                                    </paragraph>
                                    <paragraph>The initial starting dose is 0.2 mg to 1 mg every 2 to 3 hours.  Intravenous administration should be given <content styleCode="underline">slowly</content>, over at least 2 to 3 minutes, depending on the dose. The initial dose should be reduced in the elderly or debilitated and may be lowered to 0.2 mg.
</paragraph>
                                 </text>
                                 <effectiveTime value="20200131"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s15">
                           <id root="9d039715-49b5-4101-85ba-55d768828aa6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Conversion From Other Opioids to DILAUDID INJECTION:</content>
                              </paragraph>
                              <paragraph>There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of DILAUDID INJECTION. It is safer to underestimate a patient's 24-hour DILAUDID INJECTION dosage than to overestimate the 24-hour DILAUDID INJECTION dosage and manage an adverse reaction due to overdose.
</paragraph>
                              <paragraph>If the decision is made to convert to Hydromorphone Hydrochloride Injection from another opioid analgesic using publicly available data, convert the current total daily amount(s) of opioid(s) received to an equivalent total daily dose of DILAUDID INJECTION and reduce by one-half due to the possibility of incomplete cross tolerance.  Divide the new total amount by the number of doses permitted based on dosing interval (e.g., 8 doses for every-three-hour dosing).  Titrate the dose according to the patient's response.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="e3af9460-da75-43c3-b61d-3bcddd080030"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Modifications in Patients with Hepatic Impairment
</title>
                     <text>
                        <paragraph>Start patients with hepatic impairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the extent of impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s77">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="e927718f-f8ce-479f-af22-4fe077691613"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modifications in Patients with Renal Impairment
</title>
                     <text>
                        <paragraph>Start patients with renal impairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the degree of impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s77">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="4867a217-6c00-479a-b7d7-f8ff9ecba06d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Titration and Maintenance of Therapy
</title>
                     <text>
                        <paragraph>Individually titrate DILAUDID INJECTION to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving DILAUDID INJECTION to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.1</linkHtml>)]</content>. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
</paragraph>
                        <paragraph>If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID INJECTION dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="4cf01536-9260-4760-8b25-19029edb5522"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Discontinuation of DILAUDID INJECTION
</title>
                     <text>
                        <paragraph>When a patient who has been taking DILAUDID INJECTION regularly and may be physically dependent no longer requires therapy with DILAUDID INJECTION, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue DILAUDID INJECTION in a physically-dependent patient <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s35">5.11</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#s62">9.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="b22c965f-1267-4767-9f5f-dd62d012a018"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>DILAUDID INJECTION:
</paragraph>
                  <paragraph>Each single-dose prefilled syringe contains 0.2 mg/mL, 0.5 mg/0.5 mL, 1 mg/mL or 2 mg/mL of hydromorphone hydrochloride in a sterile, aqueous solution.
</paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>DILAUDID Injection, 0.2 mg/mL, 0.5 mg/0.5mL, 1 mg/mL or 2 mg/mL are available in single-dose prefilled syringes.  (<linkHtml href="#s20">3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="e10d7be4-8d74-4102-93df-b3199b3618c3"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>DILAUDID INJECTION is contraindicated in patients with:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Significant respiratory depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)]</content>
                     </item>
                     <item>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)]</content>
                     </item>
                     <item>Known or suspected gastrointestinal obstruction, including paralytic ileus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s33">5.9</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity to hydromorphone, hydromorphone salts, any other components of the product, or sulfite containing medications (e.g., anaphylaxis) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s37">5.13</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Significant respiratory depression. (<linkHtml href="#s21">4</linkHtml>)
</item>
                           <item>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. (<linkHtml href="#s21">4</linkHtml>)
</item>
                           <item>Known or suspected gastrointestinal obstruction, including paralytic ileus. (<linkHtml href="#s21">4</linkHtml>)
</item>
                           <item>Known hypersensitivity to hydromorphone, hydromorphone salts, sulfite-containing medications, or any other components of the product. (<linkHtml href="#s21">4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s22">
               <id root="772f05e2-f47a-478c-89c3-9496067950f0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients:</content> Monitor closely, particularly during initiation and titration. (<linkHtml href="#s27">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Adrenal Insufficiency:</content> If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (<linkHtml href="#s30">5.6</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Severe Hypotension:</content> Monitor during dosage initiation and titration. Avoid use of DILAUDID INJECTION in patients with circulatory shock. (<linkHtml href="#s31">5.7</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness:</content> Monitor for sedation and respiratory depression. Avoid use of DILAUDID INJECTION in patients with impaired consciousness or coma. (<linkHtml href="#s32">5.8</linkHtml>)
</item>
                           <item>DILAUDID INJECTION contains sodium metabisulfite. There is a risk of anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people. (<linkHtml href="#s37">5.13</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s23">
                     <id root="8edde393-a0b5-4d76-8006-932a02d96315"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Addiction, Abuse, and Misuse
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION contains hydromorphone, a Schedule II controlled substance. As an opioid, DILAUDID INJECTION exposes users to the risks of addiction, abuse, and misuse <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#s58">9</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed DILAUDID INJECTION. Addiction can occur at recommended dosages and if the drug is misused or abused.
</paragraph>
                        <paragraph>Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing DILAUDID INJECTION and monitor all patients receiving DILAUDID INJECTION for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as DILAUDID INJECTION but use in such patients necessitates intensive counseling about the risks and proper use of DILAUDID INJECTION along with intensive monitoring for signs of addiction, abuse, and misuse.
</paragraph>
                        <paragraph>Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing DILAUDID INJECTION. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="de981b47-9a09-4c8c-8da2-b1e230cb0cee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Life-Threatening Respiratory Depression
</title>
                     <text>
                        <paragraph>Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status <content styleCode="italics">[see Overdosage (<linkHtml href="#s63">10</linkHtml>)]</content>. Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.
</paragraph>
                        <paragraph>While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of DILAUDID INJECTION, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with and following dosage increases of DILAUDID INJECTION.
</paragraph>
                        <paragraph>To reduce the risk of respiratory depression, proper dosing and titration of DILAUDID INJECTION is essential <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s9">2</linkHtml>)].</content> Overestimating the DILAUDID INJECTION dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.
</paragraph>
                        <paragraph>Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s19">2.6</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="200e9777-7536-4c0b-8d26-fbcfbace66f6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Neonatal Opioid Withdrawal Syndrome
</title>
                     <text>
                        <paragraph>Prolonged use of DILAUDID INJECTION during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly.  Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s43">8.1</linkHtml>), Patient Counseling Information (<linkHtml href="#s87">17</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="e58dfd70-2c94-4e14-bf88-9f3c6b58ed61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants
</title>
                     <text>
                        <paragraph>Profound sedation, respiratory depression, coma, and death may result from the concomitant use of DILAUDID Injection with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
</paragraph>
                        <paragraph>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone.  Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s41">7</linkHtml>)]</content>.
</paragraph>
                        <paragraph>If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation.
</paragraph>
                        <paragraph>Advise both patients and caregivers about the risks of respiratory depression and sedation when DILAUDID Injection is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s41">7</linkHtml>) and Patient Counseling Information (<linkHtml href="#s87">17</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s27">
                     <id root="a6d0454a-b37b-455e-88c6-310f69667d94"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients
</title>
                     <text>
                        <paragraph>The use of DILAUDID INJECTION in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s28">
                           <id root="e5b89233-060b-464e-afe6-4f49e1eca92e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patients with Chronic Pulmonary Disease:</content> DILAUDID INJECTION treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of DILAUDID INJECTION <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s29">
                           <id root="4cb30b33-fc34-44f9-a56a-00a29cc4a4df"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elderly, Cachectic, or Debilitated Patients:</content> Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)].</content>
                              </paragraph>
                              <paragraph>Monitor such patients closely, particularly when initiating and titrating DILAUDID INJECTION and when DILAUDID INJECTION is given concomitantly with other drugs that depress respiration <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)].</content> Alternatively, consider the use of non-opioid analgesics in these patients.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s30">
                     <id root="930d7bee-b719-475c-b9c3-549071ab885c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Adrenal Insufficiency
</title>
                     <text>
                        <paragraph>Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="3dc64aeb-e9b6-4bc0-8edb-b098b188ecc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Severe Hypotension
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s41">7</linkHtml>)]</content>. Monitor these patients for signs of hypotension after initiating or titrating the dosage of DILAUDID INJECTION. In patients with circulatory shock, DILAUDID INJECTION may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of DILAUDID INJECTION in patients with circulatory shock.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="19f01481-30dc-48fa-97be-bf04e994d613"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness
</title>
                     <text>
                        <paragraph>In patients who may be susceptible to the intracranial effects of CO<sub>2</sub> retention (e.g., those with evidence of increased intracranial pressure or brain tumors), DILAUDID INJECTION may reduce respiratory drive, and the resultant CO<sub>2</sub> retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with DILAUDID INJECTION.
</paragraph>
                        <paragraph>Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of DILAUDID INJECTION in patients with impaired consciousness or coma.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="faf7f10c-ef24-46e1-bcf9-0af4d7270860"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risks of Use in Patients with Gastrointestinal Conditions
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
</paragraph>
                        <paragraph>The hydromorphone in DILAUDID INJECTION may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="5d164510-bf4d-45f5-9bb1-28cba6db211b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Increased Risk of Seizures in Patients with Seizure Disorders
</title>
                     <text>
                        <paragraph>The hydromorphone in DILAUDID INJECTION may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during DILAUDID INJECTION therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s35">
                     <id root="38863d7e-1c91-4cde-9560-5769b2061809"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Withdrawal
</title>
                     <text>
                        <paragraph>Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including DILAUDID INJECTION. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s41">7</linkHtml>)]</content>.
</paragraph>
                        <paragraph>When discontinuing DILAUDID INJECTION in a physically-dependent patient, gradually taper the dosage <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s19">2.6</linkHtml>)].</content> Do not abruptly discontinue DILAUDID INJECTION in these patients <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#s62">9.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s36">
                     <id root="7a47d9c9-2549-4bff-9347-2dc7e3dcdd71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Risks of Driving and Operating Machinery
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of DILAUDID INJECTION and know how they will react to the medication <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#s87">17</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="d1c1f619-84cc-4861-b3a4-4ca3ab7b3a22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Sulfites
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s38">
                     <id root="8df2f1fe-1691-4c8a-9bf5-18dc7dde7729"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION may be given intravenously, but the injection should be given very slowly. Rapid intravenous injection of opioid analgesics increases the possibility of side effects such as hypotension and respiratory depression <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s9">2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s39">
               <id root="935141a1-c244-43ae-848e-d33715d2e6fa"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
                  <paragraph>The following serious adverse reactions are described, or described in greater detail, in other sections:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Addiction, Abuse, and Misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.1</linkHtml>)]</content>
                     </item>
                     <item>Life-Threatening Respiratory Depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)]</content>
                     </item>
                     <item>Neonatal Opioid Withdrawal Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.3</linkHtml>)]</content>
                     </item>
                     <item>Interactions with Benzodiazepines and Other CNS Depressants <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.4</linkHtml>)]</content>
                     </item>
                     <item>Adrenal Insufficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s30">5.6</linkHtml>)]</content>
                     </item>
                     <item>Severe Hypotension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s31">5.7</linkHtml>)]</content>
                     </item>
                     <item>Gastrointestinal Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s33">5.9</linkHtml>)]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s34">5.10</linkHtml>)]</content>
                     </item>
                     <item>Withdrawal <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s35">5.11</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions associated with the use of hydromorphone were identified in clinical studies or postmarketing reports.  Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</paragraph>
                  <paragraph>Serious adverse reactions associated with DILAUDID INJECTION include respiratory depression and apnea and, to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest.
</paragraph>
                  <paragraph>The most common adverse effects are lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus. These effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain.
</paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus. (<linkHtml href="#s39">6</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report Suspected Adverse Reactions, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or
</content>
                           <content styleCode="bold italics">www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s40">
                     <id root="2efef5d2-586e-4835-ba26-6d17440a506f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Less Frequently Observed Adverse Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac disorders:</content> tachycardia, bradycardia, palpitations
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye disorders:</content> vision blurred, diplopia, miosis, visual impairment
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal disorders:</content> constipation, ileus, diarrhea, abdominal pain
</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions:</content> weakness, feeling abnormal<content styleCode="italics">,</content> chills, injection site urticaria, fatigue, injection site reactions, peripheral edema
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary disorders:</content> biliary colic
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders</content>: anaphylactic reactions, hypersensitivity reactions
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> hepatic enzymes increased
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders:</content> decreased appetite
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders:</content> muscle rigidity
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders:</content> headache, tremor, paraesthesia, nystagmus, increased intracranial pressure, syncope, taste alteration<content styleCode="italics">,</content> involuntary muscle contractions, presyncope, convulsion, drowsiness, dyskinesia, hyperalgesia, lethargy, myoclonus, somnolence
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders:</content> agitation, mood altered, nervousness, anxiety<content styleCode="italics">,</content> depression, hallucination, disorientation, insomnia, abnormal dreams
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders:</content> urinary retention, urinary hesitation, antidiuretic effects
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive system and breast disorders:</content> erectile dysfunction
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic, and mediastinal disorders:</content> bronchospasm, laryngospasm, dyspnea, oropharyngeal swelling
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> injection site pain, urticaria, rash, hyperhidrosis
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular disorders:</content> flushing, hypotension, hypertension
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Serotonin syndrome</content>: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adrenal insufficiency</content>: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Anaphylaxis</content>: Anaphylaxis has been reported with ingredients contained in DILAUDID INJECTION.
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Androgen deficiency</content>: Cases of androgen deficiency have occurred with chronic use of opioids <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s69">12.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s41">
               <id root="1d785473-fca3-46a0-971f-4489aa1039bf"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <text>
                  <paragraph>
                     <linkHtml href="#t1">Table 1</linkHtml> includes clinically significant drug interactions with DILAUDID INJECTION.
</paragraph>
                  <table ID="t1" width="100%">
                     <caption>TABLE 1. Clinically Significant Drug Interactions with DILAUDID INJECTION
</caption>
                     <col width="25.900%" align="left"/>
                     <col width="74.100%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Benzodiazepines and other Central Nervous System Depressants (CNS)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)]</content>.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Serotonergic Drugs</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue DILAUDID INJECTION if serotonin syndrome is suspected.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e. cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.2</linkHtml>)]</content>.<br/>If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">The use of DILAUDID INJECTION is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">phenelzine, tranylcypromine, linezolid
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">May reduce the analgesic effect of DILAUDID INJECTION and/or precipitate withdrawal syndrome.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Avoid concomitant use.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">butorphanol, nalbuphine, pentazocine, buprenorphine
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Muscle Relaxants</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Hydromorphone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of DILAUDID INJECTION and/or the muscle relaxant as necessary.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Diuretics</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Anticholinergic Drugs</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
</td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Monitor patients for signs of urinary retention or reduced gastric motility when DILAUDID INJECTION is used concomitantly with anticholinergic drugs.
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Serotonergic Drugs:</content> Concomitant use may result in serotonin syndrome. Discontinue DILAUDID INJECTION if serotonin syndrome is suspected. (<linkHtml href="#s41">7</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Monoamine Oxidase Inhibitors (MAOIs)</content>: Can potentiate the effects of hydromorphone.  Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI. (<linkHtml href="#s41">7</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics:</content> Avoid use with DILAUDID INJECTION because they may reduce analgesic effect of DILAUDID INJECTION or precipitate withdrawal symptoms. (<linkHtml href="#s41">7</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s42">
               <id root="20144c0e-2b35-47cc-a676-57f7637cb916"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20200131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy: May cause fetal harm. (<linkHtml href="#s43">8.1</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s43">
                     <id root="82a86447-5f9e-45db-a834-f3e6fd66fb3c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s44">
                           <id root="4e46d7b6-660c-46a6-8e19-2d9fdae15713"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.3</linkHtml>)]</content>.  There are no available data with DILAUDID injection in pregnant women to inform a drug-associated risk for major birth defects and miscarriage.
</paragraph>
                              <paragraph>In animal reproduction studies, reduced postnatal survival of pups, and decreased body weight were noted following oral treatment of pregnant rats with hydromorphone during gestation and through lactation at doses 0.8 times the human daily dose of 24 mg/day (HDD), respectively.  In published studies, neural tube defects were noted following subcutaneous injection of hydromorphone to pregnant hamsters at doses 6.4 times the HDD and soft tissue and skeletal abnormalities were noted following subcutaneous continuous infusion of 3 times the HDD to pregnant mice.  No malformations were noted at 4 or 40.5 times the HDD in pregnant rats or rabbits, respectively [<content styleCode="italics">see <linkHtml href="#s47">Data</linkHtml>
                                 </content>].  Based on animal data, advise pregnant women of the potential risk to a fetus.
</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s45">
                           <id root="c947361b-25fb-4d6e-98e8-cf477d4a343b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <caption> 
</caption>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.
</paragraph>
                                    <paragraph>Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.3</linkHtml>)].</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Labor or Delivery</content>
                                    </paragraph>
                                    <paragraph>Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. DILAUDID INJECTION is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including DILAUDID INJECTION, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.
</paragraph>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s47">
                           <id root="ffd7d45e-671f-47e5-87f9-bd5f9f0e9799"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <caption> 
</caption>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Pregnant rats were treated with hydromorphone hydrochloride from Gestation Day 6 to 17 via oral gavage doses of 1, 5, or 10 mg/kg/day (0.4, 2, or 4 times the HDD of 24 mg based on body surface area, respectively).  Maternal toxicity was noted in all treatment groups (reduced food consumption and body weights in the two highest dose groups).  There was no evidence of malformations or embryotoxicity reported.
</paragraph>
                                    <paragraph>Pregnant rabbits were treated with hydromorphone hydrochloride from Gestation Day 7 to 19 via oral gavage doses of 10, 25, or 50 mg/kg/day (8.1, 20.3, or 40.5 times the HDD of 24 mg based on body surface area, respectively).  Maternal toxicity was noted in the two highest dose groups (reduced food consumption and body weights).  There was no evidence of malformations or embryotoxicity reported.
</paragraph>
                                    <paragraph>In a published study, neural tube defects (exencephaly and cranioschisis) were noted following subcutaneous administration of hydromorphone hydrochloride (19 to 258 mg/kg) on Gestation Day 8 to pregnant hamsters (6.4 to 87.2 times the HDD of 24 mg/day based on body surface area).  The findings cannot be clearly attributed to maternal toxicity.  No neural tube defects were noted at 14 mg/kg (4.7 times the human daily dose of 24 mg/day).
</paragraph>
                                    <paragraph>In a published study, CF-1 mice were treated subcutaneously with continuous infusion of 7.5, 15, or 30 mg/kg/day hydromorphone hydrochloride (1.5, 3, or 6.1 times the human daily dose of 24 mg based on body surface area) via implanted osmotic pumps during organogenesis (Gestation Days 7 to 10).  Soft tissue malformations (cryptorchidism, cleft palate, malformed ventricles and retina), and skeletal variations (split supraoccipital, checkerboard and split sternebrae, delayed ossification of the paws and ectopic ossification sites) were observed at doses 3 times the human dose of 24 mg/day based on body surface area.  The findings cannot be clearly attributed to maternal toxicity.
</paragraph>
                                    <paragraph>Increased pup mortality and decreased pup body weights were noted at 0.8 and 2 times the human daily dose of 24 mg in a study in which pregnant rats were treated with hydromorphone hydrochloride from Gestation Day 7 to Lactation Day 20 via oral gavage doses of 0, 0.5, 2, or 5 mg/kg/day (0.2, 0.8, or 2 times the HDD of 24 mg based on body surface area, respectively). Maternal toxicity (decreased food consumption and body weight gain) was also noted at the two highest doses tested.
</paragraph>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s49">
                     <id root="7eb0de82-467f-4592-abe5-7e3bdc65a99e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s50">
                           <id root="b3270603-3957-4ecf-a178-033b0f88f472"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Low levels of opioid analgesics have been detected in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DILAUDID INJECTION and any potential adverse effects on the breastfed infant from DILAUDID INJECTION or from the underlying maternal condition.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s51">
                           <id root="46d7fc4d-6353-400e-ae0d-f59c3b949c31"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Monitor infants exposed to DILAUDID INJECTION through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of hydromorphone is stopped, or when breast-feeding is stopped.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s52">
                     <id root="87e2ac7b-9c56-4bba-8977-d9f7ff74a1e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s53">
                           <id root="ed960060-1731-4642-9db7-2735283588b7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>Chronic use of opioids may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s39">6</linkHtml>), Clinical Pharmacology (<linkHtml href="#s69">12.2</linkHtml>), Nonclinical Toxicology (<linkHtml href="#s82">13.1</linkHtml>)].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="869682e2-631b-46c2-91b9-e6e25965c044"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of DILAUDID INJECTION in pediatric patients has not been established.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s55">
                     <id root="fcb6804c-7c17-4be5-ab0b-e350762a760e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Elderly patients (aged 65 years or older) may have increased sensitivity to hydromorphone.  In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
</paragraph>
                        <paragraph>Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of DILAUDID INJECTION slowly in geriatric patients and monitor closely for signs of central nervous system and respiratory depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s27">5.5</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Hydromorphone is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s56">
                     <id root="24158053-cc94-42a4-af4f-2190c32ecbe4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment
</title>
                     <text>
                        <paragraph>The pharmacokinetics of hydromorphone are affected by hepatic impairment. Due to increased exposure of hydromorphone, patients with moderate hepatic impairment should be started at one-fourth to one-half the recommended starting dose depending on the degree of hepatic dysfunction and closely monitored during dose titration. The pharmacokinetics of hydromorphone in patients with severe hepatic impairment has not been studied. A further increase in C<sub>max</sub> and AUC of hydromorphone in this group is expected and should be taken into consideration when selecting a starting dose <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s77">12.3</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s57">
                     <id root="b17f554f-b567-4014-98a0-009066de3665"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment
</title>
                     <text>
                        <paragraph>The pharmacokinetics of hydromorphone are affected by renal impairment. Start patients with renal impairment on one-fourth to one-half the usual starting dose depending on the degree of impairment. Patients with renal impairment should be closely monitored during dose titration <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s77">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s58">
               <id root="5e9c7c8b-616e-4068-9eea-01c5937cb65d"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE
</title>
               <effectiveTime value="20200131"/>
               <component>
                  <section ID="s59">
                     <id root="9a853c7b-7705-4c69-8dd3-c9713e1871b5"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION contains hydromorphone, which is a Schedule II controlled substance.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s60">
                     <id root="6d15d00b-c82f-42ce-9afa-e8fb9ef96796"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse
</title>
                     <text>
                        <paragraph>DILAUDID INJECTION contains hydromorphone hydrochloride, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. DILAUDID INJECTION can be abused and is subject to misuse, addiction, and criminal diversion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.
</paragraph>
                        <paragraph>Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.
</paragraph>
                        <paragraph>Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.
</paragraph>
                        <paragraph>“Drug-seeking” behavior is very common in persons with substance use disorders.  Drug-seeking tactics include, emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering of prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare providers. “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction.  Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.
</paragraph>
                        <paragraph>Abuse and addiction are separate and distinct from physical dependence and tolerance. Healthcare providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.
</paragraph>
                        <paragraph>DILAUDID INJECTION, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful recordkeeping of prescribing information, including quantity, frequency, and renewal requests as required by state and federal law, is strongly advised.
</paragraph>
                        <paragraph>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s61">
                           <id root="d6c386ff-1649-4d92-a89e-5b07ed80cebf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risks Specific to Abuse of DILAUDID INJECTION</content>
                              </paragraph>
                              <paragraph>Abuse of DILAUDID INJECTION poses a risk of overdose and death.  The risk is increased with concurrent use of DILAUDID INJECTION with alcohol and other central nervous system depressants.
</paragraph>
                              <paragraph>Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s62">
                     <id root="2ed8a0ce-5aa4-4ed5-a300-66434cb186ef"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence
</title>
                     <text>
                        <paragraph>Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.
</paragraph>
                        <paragraph>Physical dependence results in withdrawal symptoms after abrupt discontinuation of a significant dosage reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.
</paragraph>
                        <paragraph>DILAUDID INJECTION should not be abruptly discontinued in a physically-dependent patient <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s19">2.6</linkHtml>)]</content>.  If DILAUDID INJECTION is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s43">8.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s63">
               <id root="a2aba1a4-f44a-4b4c-b7c8-f281d4354ce2"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <effectiveTime value="20200131"/>
               <component>
                  <section ID="s64">
                     <id root="7d278893-950d-402c-81bb-9864c1e99583"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Clinical Presentation</content>
                        </paragraph>
                        <paragraph>Acute overdose with DILAUDID INJECTION can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis, rather than miosis, may be seen with hypoxia in overdose situations [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#s69">12.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s65">
                     <id root="8f9392fd-f7c3-44d0-9c10-424fce83605b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Treatment of Overdose</content>
                        </paragraph>
                        <paragraph>In case of overdose, priorities are the reestablishment of a patent airway and protected airway and institution of assisted or controlled ventilation, if needed.  Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques.
</paragraph>
                        <paragraph>The opioid antagonists, naloxone or nalmefene are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to hydromorphone overdose, administer an opioid antagonist.  Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to hydromorphone overdose.
</paragraph>
                        <paragraph>Because the duration of opioid reversal is expected to be less than the duration of hydromorphone in DILAUDID INJECTION, carefully monitor the patient until spontaneous respiration is reliably reestablished.  If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information.
</paragraph>
                        <paragraph>In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s66">
               <id root="719befd9-db99-4f4a-afa5-292a2a67335b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid agonist.
</paragraph>
                  <paragraph>DILAUDID INJECTION is available as a sterile, aqueous solution in clear and colorless single-dose prefilled syringes for slow intravenous, subcutaneous, or intramuscular administration. Each 1 mL of solution contains 0.2 mg, 1 mg or 2 mg of hydro- morphone hydrochloride.
</paragraph>
                  <paragraph>The chemical name of DILAUDID is 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The molecular weight is 321.80.  Its molecular formula is C<sub>17</sub>H<sub>19</sub>NO<sub>3</sub>·HCl, and it has the following chemical structure:
</paragraph>
                  <paragraph>                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  </paragraph>
                  <paragraph>Hydromorphone hydrochloride is a white or almost white crystalline powder that is freely soluble in water, very slightly soluble in ethanol (96%), and practically insoluble in methylene chloride.
</paragraph>
                  <paragraph>The inactive ingredients in DILAUDID (hydromorphone hydrochloride) include: 0.2% sodium citrate and 0.2% citric acid added as a buffer to maintain a pH between 3.5 and 5.5.
</paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Chemical Structure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s67">
               <id root="bf557362-b089-4408-9862-116079a07098"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20200131"/>
               <component>
                  <section ID="s68">
                     <id root="e445fb0f-ae91-40ef-a679-13596441ab91"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Hydromorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses.  The principal therapeutic action of hydromorphone is analgesia.  Like all full opioid agonists, there is no ceiling effect for analgesia with morphine.  Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
</paragraph>
                        <paragraph>The precise mechanism of the analgesic action is unknown.  However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s69">
                     <id root="15315803-8292-4a57-9263-9ab30f06e5b3"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s70">
                           <id root="69565cd0-c482-4b8f-906d-95d2e31e5bb8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Central Nervous System</content>
                              </paragraph>
                              <paragraph>Hydromorphone produces respiratory depression by direct effect on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.
</paragraph>
                              <paragraph>Hydromorphone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings).  Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s71">
                           <id root="fd685ce8-681a-4746-871f-c629ca2f3813"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Gastrointestinal Tract and Other Smooth Muscle</content>
                              </paragraph>
                              <paragraph>Hydromorphone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s72">
                           <id root="8bc42800-bedb-41ca-8956-14f4926ed059"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Cardiovascular System</content>
                              </paragraph>
                              <paragraph>Hydromorphone produces peripheral vasodilation which may result in orthostatic hypotension or syncope, manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, and sweating and/or orthostatic hypotension.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s73">
                           <id root="5f868da4-ebc5-42b2-9037-dfb34b0b689c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Endocrine System</content>
                              </paragraph>
                              <paragraph>Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s39">6</linkHtml>)]</content>.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.
</paragraph>
                              <paragraph>Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s39">6</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s74">
                           <id root="1e520a2e-6406-418d-8bbe-1be41e88f6d7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Immune System</content>
                              </paragraph>
                              <paragraph>Opioids have been shown to have a variety of effects on components of the immune system in <content styleCode="italics">in vitro</content> and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s75">
                           <id root="caf0fb8d-62b5-41c5-af9b-88922657aa94"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concentration–Efficacy Relationships</content>
                              </paragraph>
                              <paragraph>The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. The minimum effective analgesic concentration of hydromorphone for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the development of analgesic tolerance <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s10">2.1</linkHtml>, <linkHtml href="#s11">2.2</linkHtml>)]</content> .
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s76">
                           <id root="f5a40012-ae3c-42da-a016-83af1670623d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concentration–Adverse Reaction Relationships</content>
                              </paragraph>
                              <paragraph>There is a relationship between increasing hydromorphone plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s10">2.1</linkHtml>, <linkHtml href="#s11">2.2</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s77">
                     <id root="00e0a7a0-e6aa-465c-9e20-29e9b2b371df"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s78">
                           <id root="20fd42db-2736-498e-a9b1-485b2ec64bb9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>At therapeutic plasma levels, hydromorphone is approximately 8-19% bound to plasma proteins. After an intravenous bolus dose, the steady state of volume of distribution [mean (%CV)] is 302.9 (32%) liters.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s79">
                           <id root="d0509761-88b7-4a9f-a6fd-e11eabce80c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The systemic clearance is approximately 1.96 (20%) liters/minute. The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.
</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption> 
</caption>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Hydromorphone is extensively metabolized via glucuronidation in the liver, with greater than 95% of the dose metabolized to hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.
</paragraph>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s80">
                           <id root="8ebe1065-1831-4f34-a90e-4a9a9ddbfab5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Special Populations</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption> 
</caption>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>After oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets), mean exposure to hydromorphone (C<sub>max</sub> and AUC∞) is increased 4-fold in patients with moderate (Child-Pugh Group B) hepatic impairment compared with subjects with normal hepatic function. Patients with moderate hepatic impairment should be started at one-fourth to one-half the recommended starting dose and closely monitored during dose titration. The pharmacokinetics of hydromorphone in patients with severe hepatic impairment has not been studied. A further increase in C<sub>max</sub> and AUC of hydromorphone in this group is expected and should be taken into consideration when selecting a starting dose [see Use in Specific Populations (<linkHtml href="#s56">8.6</linkHtml>)].
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of hydromorphone following an oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets) are affected by renal impairment. Mean exposure to hydromorphone (C<sub>max</sub> and AUC0-∞) is increased by 2-fold in patients with moderate (CLcr = 40 - 60 mL/min) renal impairment and increased by 4-fold in patients with severe (CLcr&lt; 30 mL/min) renal impairment compared with normal subjects (CLcr&gt; 80 mL/min). In addition, in patients with severe renal impairment, hydromorphone appeared to be more slowly eliminated with a longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr).  Start patients with renal impairment on one-fourth to one-half the usual starting dose depending on the degree of impairment. Patients with renal impairment should be closely monitored during dose titration [see Use in Specific Populations (<linkHtml href="#s57">8.7</linkHtml>)].
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Population</content>
                                    </paragraph>
                                    <paragraph>In the geriatric population, age has no effect on the pharmacokinetics of hydromorphone.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Sex</content>
                                    </paragraph>
                                    <paragraph>Sex has little effect on the pharmacokinetics of hydromorphone. Females appear to have a higher C<sub>max</sub> (25%) than males with comparable AUC0-24 values. The difference observed in C<sub>max</sub> may not be clinically relevant.
</paragraph>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s81">
               <id root="56eda562-b63e-4f0f-96ca-adcd00604455"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20200131"/>
               <component>
                  <section ID="s82">
                     <id root="45c067b3-d20d-4875-aae8-676f24a3fdb2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <effectiveTime value="20200131"/>
                     <component>
                        <section ID="s83">
                           <id root="7fe7c940-46d5-4b65-ba59-a1df67fa4076"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long term studies in animals to evaluate the carcinogenic potential of hydromorphone have not been conducted.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s84">
                           <id root="8fe2ae46-b71f-4fec-af6b-dabea5aa1a97"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Hydromorphone was positive in the mouse lymphoma assay in the presence of metabolic activation, but was negative in the mouse lymphoma assay in the absence of metabolic activation.  Hydromorphone was not mutagenic in the <content styleCode="italics">in vitro</content> bacterial reverse mutation assay (Ames assay).  Hydromorphone was not clastogenic in either the <content styleCode="italics">in vitro</content> human lymphocyte chromosome aberration assay or the <content styleCode="italics">in vivo</content> mouse micronucleus assay.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s85">
                           <id root="8bcfa31e-a65d-4026-8d42-8113997b6e47"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Reduced implantation sites and viable fetuses were noted at 2.1 times the human daily dose of 32 mg/day in a study in which female rats were treated orally with 1.75, 3.5, or 7 mg/kg/day hydromorphone hydrochloride (0.5, 1.1, or 2.1 times a human daily dose of 24 mg/day (HDD) based on body surface area) beginning 14 days prior to mating through Gestation Day 7 and male rats were treated with the same hydromorphone hydrochloride doses beginning 28 days prior to and throughout mating.
</paragraph>
                           </text>
                           <effectiveTime value="20200131"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s86">
               <id root="133737c3-3dfa-48ca-af26-a1a4884e29a6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>DILAUDID INJECTION (hydromorphone hydrochloride) is supplied in clear and colorless single-dose prefilled syringes. Each single-dose prefilled syringe of sterile, aqueous solution contains 0.2 mg, 0.5 mg, 1 mg or 2 mg hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid solution.
</paragraph>
                  <paragraph>DILAUDID INJECTION contains no added preservative and is supplied as follows:
</paragraph>
                  <table width="100%">
                     <col width="19.400%" align="left"/>
                     <col width="23.050%" align="left"/>
                     <col width="19.400%" align="left"/>
                     <col width="38.150%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Product Code</content>
                           </td>
                           <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Unit of Sale</content>
                           </td>
                           <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Each</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">771906
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-009-06 Unit of 10
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">0.5 mg/0.5 mL
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-009-96<br/>0.5 mL single-dose prefilled syringe
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">771911
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-009-11 Unit of 10
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">1 mg/mL
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-009-01<br/>1 mL single-dose prefilled syringe
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">771011
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-010-11 Unit of 10
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">2 mg/mL
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-010-01<br/>1 mL single-dose prefilled syringe
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">771311
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-121-11 Unit of 10
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">0.2 mg/mL
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 76045-121-01<br/>1 mL single-dose prefilled syringe
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>PROTECT FROM LIGHT.
</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Safety and Handling Instructions</content>
                  </paragraph>
                  <paragraph>Discard any unused portion.
</paragraph>
                  <paragraph>Access to drugs with a potential for abuse such as DILAUDID INJECTION presents an occupational hazard for addiction in the health care industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect health care workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by health care providers.
</paragraph>
               </text>
               <effectiveTime value="20200131"/>
            </section>
         </component>
         <component>
            <section ID="s87">
               <id root="a0ff4a9f-dc43-4209-a91d-4abd3612bdd8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <effectiveTime value="20200131"/>
               <component>
                  <section ID="s88">
                     <id root="c020d393-c1ad-4308-9cd7-054763e6bbd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serotonin Syndrome</content>
                        </paragraph>
                        <paragraph>Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take serotonergic medications, <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s41">7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
               <component>
                  <section ID="s89">
                     <id root="a6a49124-3e95-446b-9305-c95774454efa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Constipation</content>
                        </paragraph>
                        <paragraph>Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s39">6</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Healthcare professionals can telephone Fresenius Kabi USA, LLC at 1-800-551-7176 for information or to report adverse events on this product.
</paragraph>
                     </text>
                     <effectiveTime value="20200131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s90">
               <id root="d8766e35-1bca-4de7-a0b1-00f0b276e057"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Figure 1: Outer Packaging (MicroVault</content>
                     <content styleCode="underline">
                        <sup>®</sup>
                     </content>
                     <content styleCode="underline">) and Prefilled Syringe</content>
                  </paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
                  <paragraph>NOTES:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <caption>-
</caption>Do not introduce any other fluid into the syringe at any time.
</item>
                     <item>
                        <caption>-
</caption>Do not dilute for IV push.
</item>
                     <item>
                        <caption>-
</caption>Do not re-sterilize the syringe.
</item>
                     <item>
                        <caption>-
</caption>Do not use this product on a sterile field.
</item>
                     <item>
                        <caption>-
</caption>This product is for single dose only.
</item>
                  </list>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Once removed from the bundle, inspect the outer packaging by verifying:<list listType="unordered" styleCode="Disc">
                           <item>
                              <caption>-
</caption>Integrity of the tube and the cap.
</item>
                           <item>
                              <caption>-
</caption>Tamper evident seal is intact (outer shrink wrap is not broken).<br/>
                           </item>
                        </list>
                        <content styleCode="bold">Do not use if the outer packaging has been damaged.</content>
                     </item>
                     <item>
                        <paragraph>Hold the outer packaging with both hands. To break the tamper evident seal, hold the tube and the cap close to the seal, and twist until broken. (See <linkHtml href="#fig2">Figure 2</linkHtml>)
</paragraph>
                        <paragraph ID="fig2">
                           <content styleCode="underline">Figure 2</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="f03" referencedObject="mm03"/>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Remove the cap of the outer packaging by pulling it straight away from the tube to avoid dislodging the plunger rod of the syringe. (See <linkHtml href="#fig3">Figure 3</linkHtml>)
</paragraph>
                        <paragraph ID="fig3">
                           <content styleCode="underline">Figure 3</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="f04" referencedObject="mm04"/>
                        </paragraph>
                     </item>
                     <item>Remove the syringe from the tube.
</item>
                     <item>Visually inspect the syringe. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
</item>
                     <item>
                        <paragraph>Twist off the syringe tip cap. Do not remove the plastic wrap label around the luer lock collar. (See <linkHtml href="#fig4">Figure 4</linkHtml>)
</paragraph>
                        <paragraph ID="fig4">
                           <content styleCode="underline">Figure 4</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="f05" referencedObject="mm05"/>
                        </paragraph>
                     </item>
                     <item>Expel air bubble(s). Adjust the dose (if applicable).
</item>
                     <item>Administer the dose ensuring that pressure is maintained on the plunger rod during the entire administration.
</item>
                     <item>Discard the used syringe into an appropriate receptacle.
</item>
                  </list>
                  <paragraph>For more information concerning this drug, please call Fresenius Kabi USA, LLC at 1-800-551-7176.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f06" referencedObject="mm06"/>
                  </paragraph>
                  <paragraph>Lake Zurich, IL 60047 <br/>www.fresenius-kabi.com/us<br/>Rev. 01/2020<br/>451594B<br/>Dilaudid is a licensed trademark of Purdue Pharma L.P.<br/>U.S. Patents 9,731,082 and 10,064,998
</paragraph>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Figure 1
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm03">
                     <text>Figure 2
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm04">
                     <text>Figure 3
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm05">
                     <text>Figure 4
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm06">
                     <text>Fresenius Kabi Logo
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s91">
               <id root="82182574-db33-42dc-beaf-164b5e7f9ea1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 0.5 mL Single-Dose Syringe Label</content>
                  </paragraph>
                  <paragraph>For SC, IM, or slow IV use. 0.5 mL Single-Dose.
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.5 mg/0.5 mL</content>
                  </paragraph>
                  <renderMultiMedia ID="f07" referencedObject="mm07"/>
               </text>
               <effectiveTime value="20240101"/>
               <component>
                  <observationMedia ID="mm07">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 0.5 mL Single-Dose Syringe Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s92">
               <id root="77e6eb1e-087c-4946-8814-1eb82ab666e8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 0.5 mL Single-Dose Tip Cap Label<br/>
                     </content>
                     <content styleCode="bold">Dilaudid<sup>®</sup> CII
</content>
                     <br/> HYDROmorphone HCl<br/> Injection, USP 
</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.5 mg per 0.5 mL
</content>
                     <br/> For Subcutaneous, IM, or slow IV use. 
</paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <renderMultiMedia ID="f08" referencedObject="mm08"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm08">
                     <text>tip
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s93">
               <id root="675010ba-c1a9-4f05-b80e-ba3fa5b5973f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 0.5 mL Single-Dose Carton Panel<br/>
                     </content>Rx only  76045-009-06<br/>
                     <content styleCode="bold">Dilaudid<sup>®</sup> CII</content>
                     <br/> HYDROmorphone HCl<br/> Injection, USP 
</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.5 mg per 0.5 mL
</content>
                     <br/> For Subcutaneous, Intramuscular, or slow Intravenous use.<br/> Do NOT dilute for IV push.<br/> Do NOT place syringe on a Sterile Field. <br/> 10 x 0.5 mL single-dose prefilled syringes<br/>
                     <content styleCode="bold">Discard unused portion.
</content>
                  </paragraph>
                  <br/>
                  <renderMultiMedia ID="f09" referencedObject="mm09"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm09">
                     <text>ct
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s94">
               <id root="bfa845ba-900d-4b78-b08f-42a2b367f91f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 1 mL Single-Dose Syringe Label</content>
                  </paragraph>
                  <paragraph>For SC, IM, or slow IV use. 1 mL Single-Dose.
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.2 mg/mL</content>
                  </paragraph>
                  <renderMultiMedia ID="f10" referencedObject="mm10"/>
               </text>
               <effectiveTime value="20240101"/>
               <component>
                  <observationMedia ID="mm10">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 1 mL Single-Dose Syringe Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s95">
               <id root="3959c7b0-c4ac-475f-838a-4108799261a2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1 mL Single-Dose Tip Cap Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.2 mg/mL</content>
                  </paragraph>
                  <paragraph>For Subcutaneous, IM, or slow IV use.
</paragraph>
                  <renderMultiMedia ID="f11" referencedObject="mm11"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm11">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1 mL Single-Dose Tip Cap Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s96">
               <id root="e714e6ac-4f36-46d6-91ed-2dea17a4847e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1mL Single-Dose Carton Panel</content>
                  </paragraph>
                  <paragraph>Rx only 76045-121-11
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.2 mg/mL</content>
                  </paragraph>
                  <paragraph>For Subcutaneous, Intramuscular, or slow Intravenous use.
</paragraph>
                  <paragraph>Do NOT dilute for IV push.
</paragraph>
                  <paragraph>Do NOT place syringe on a Sterile Field.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">10</content> x 1mL single-dose prefilled syringes
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard unused portion.</content>
                  </paragraph>
                  <renderMultiMedia ID="f12" referencedObject="mm12"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm12">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1mL Single-Dose Carton Panel
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s97">
               <id root="d80a7eef-88ae-4122-969c-f616791c7046"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 1 mL Single-Dose Syringe Label</content>
                  </paragraph>
                  <paragraph>For SC, IM, or slow IV use. 1 mL Single-Dose.
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg/mL</content>
                  </paragraph>
                  <renderMultiMedia ID="f13" referencedObject="mm13"/>
               </text>
               <effectiveTime value="20240101"/>
               <component>
                  <observationMedia ID="mm13">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 1 mL Single-Dose Syringe Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s98">
               <id root="9d440a90-3968-497b-b1b8-e7a0e67f015c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1 mL Single-Dose Tip Cap Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg/mL</content>
                  </paragraph>
                  <paragraph>For Subcutaneous, IM, or slow IV use.
</paragraph>
                  <renderMultiMedia ID="f14" referencedObject="mm14"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm14">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1 mL Single-Dose Tip Cap Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s99">
               <id root="707bb68b-f1fd-4fb9-9b34-fb2db60b8123"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1mL Single-Dose Carton Panel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only 76045-009-11</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg/mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Subcutaneous, Intramuscular, or slow Intravenous use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do NOT dilute for IV push.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do NOT place syringe on a Sterile Field.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10</content> x 1 mL single-dose prefilled syringes
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard unused portion.</content>
                  </paragraph>
                  <renderMultiMedia ID="f15" referencedObject="mm15"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm15">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1mL Single-Dose Carton Panel
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s100">
               <id root="af07f01b-e1ee-41a0-a2da-95f673c2a545"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 1 mL Single-Dose Syringe Label</content>
                  </paragraph>
                  <paragraph>For SC, IM, or slow IV use. 1 mL Single-Dose.
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilaudid</content>
                     <content styleCode="bold">
                        <sup>®
</sup>
                     </content>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>HYDROmorphone HCl
</paragraph>
                  <paragraph>Injection, USP
</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg/mL</content>
                  </paragraph>
                  <renderMultiMedia ID="f16" referencedObject="mm16"/>
               </text>
               <effectiveTime value="20240101"/>
               <component>
                  <observationMedia ID="mm16">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL –  Dilaudid 1 mL Single-Dose Syringe Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s101">
               <id root="1963285e-497c-4b08-95c7-109265591bfc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1 mL Single-Dose Tip Cap Label
</content>
                     <br/>
                     <content styleCode="bold">Dilaudid<sup>®</sup> CII
</content>
                     <br/> HYDROmorphone HCl<br/> Injection, USP 
</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg/mL</content>
                  </paragraph>
                  <paragraph>For Subcutaneous, IM, or slow IV use. 
</paragraph>
                  <renderMultiMedia ID="f17" referencedObject="mm17"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm17">
                     <text>tip
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s102">
               <id root="8808e782-e1df-4341-a67f-422b95275b22"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dilaudid 1mL Single-Dose Carton Panel<br/>
                     </content>Rx only  76045-010-11<br/>
                     <content styleCode="bold">Dilaudid<sup>®</sup> CII</content>
                     <br/> HYDROmorphone HCl<br/> Injection, USP 
</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg/mL
</content>
                     <br/> For Subcutaneous, Intramuscular, or slow Intravenous use.<br/> Do NOT dilute for IV push.<br/> Do NOT place syringe on a Sterile Field. <br/> 10 x 1mL single-dose prefilled syringes<br/>
                     <content styleCode="bold">Discard unused portion.
</content>
                  </paragraph>
                  <br/>
                  <renderMultiMedia ID="f18" referencedObject="mm18"/>
               </text>
               <effectiveTime value="20200131"/>
               <component>
                  <observationMedia ID="mm18">
                     <text>cn
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dil0a-0003-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>